SPRINGWORKS

📅 Upcoming

🕒 Recent(90d)

News

• Immutep, Molecular cut workforces
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 1d ago
• Merck KGaA makes noise in hematology with $1.1B Silence buy
  Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight race to challenge Takeda in a potential $2 billion market.
  biospace · 12d ago
• Merck KGaA bets on RNAi with $1.3B Silence buyout
  The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.
  biopharma_dive · 12d ago
• Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win
  Germany’s Merck KGaA has picked up Silence Therapeutics to the tune of $1.3 billion in the wake of the British biotech’s mid-stage success for its challenger to Takeda’s Mimrylo.
  fiercebiotech · 12d ago
• Beeline flies into phase 3 as oral lupus drug soars past placebo
  A phase 2 trial of Beeline Medicines’ afimetoran has hit its primary endpoint, positioning the biotech to swarm into pivotal development in two forms of lupus.
  fiercebiotech · 1mo ago
• Beeline ups its Series A round for immune drug work
  The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of Bristol Myers drugs.
  biopharma_dive · 4mo ago
• Fierce Biotech Layoff Tracker 2026: Enlivex excises 60%; Eyepoint halves headcount
  As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.
  fiercebiotech · 10mo ago
• Fierce Biotech Fundraising Tracker '26: Nouscom nabs $135M series D; Estuary channels $93M series A
  The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
  fiercebiotech · 10mo ago